 Organogenesis Holdings Inc. ORGO, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical Sports Medicine markets, today announced that second quarter of fiscal year 2020 financial results will be reported after the market closes on Monday, August 10. For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 404-537-3406 for international callers; access code 4153175. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. 